All In Biotech

Drug Trial Radar · NCT04681170

Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

Phase III, Single Arm, Open Label, International, Multi Centre Study to Evaluate the Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH) on Stable Lipid Lowering Therapy

Last checked: Nov 20, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

46

Actual

Start

Dec 14, 2020

Primary completion

Oct 16, 2022

Study completion Jun 6, 2024

Sponsor

Lead sponsor
Amryt PharmaIndustry
Sponsor type
Industry
First posted
Dec 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single arm, open label, multi centre phase III study to evaluate the efficacy and long term safety of lomitapide in paediatric patients with HoFH receiving stable lipid lowering therapy (LLT) (including lipoprotein apheresis (LA), when applicable) comprising of the following phases: * Screening Period (starting at Week 12, i.e. ≤12 weeks prior to Baseline for up to 6 weeks) * Stratified Enrolment and Start of Run in Period (starting at minimum at Week 6, i.e., 6 weeks prior to Baseline for a minimum of 6 weeks): * Efficacy Phase (starting at Baseline, i.e. Day \[D\] 0 for 24 weeks±3 days * Safety Phase (starting at Week 24±3 days for 80±1 weeks)

Conditions

  • Homozygous Familial Hypercholesterolaemia (HoFH)

Interventions

  • LomitapideDrug

    2mg,5mg, 10mg and 20mg capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to BaselineTime frame: Baseline through Week 24

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • University Hospital of Cologne

    Cologne, Germany

  • University Medical Center Hamburg-Eppendorf

    Hamburg, Germany

  • Universtiats-Kinderlinik Heidelberg

    Heidelberg, Baden-Wurttemberg, Germany

  • Chaim Sheba Medical Center

    Ramat Gan, Israel

  • Bambino Gesù Children's Hospital,

    Roma, Italy

  • U.O.C. Clinica Medica 1

    Padova, Padua, Italy

  • King Abdullah International Medical Research Centre (KAIMRC),

    Riyadh, Saudi Arabia

  • King Faisal Specialist Hospital

    Riyadh, Saudi Arabia

  • Hospital Abente y Lago

    A Coruña, Spain

  • Hospital Clinico Universitario of Valencia

    Valencia, Spain

  • Hospital Universitari Sant Joan

    Reus, Tarragona,, Spain

  • E.P.S. Fattouma Bourguiba Hospital

    Monastir, Tunisia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.